Pregnancy registry launched to check safety of endometriosis drug elagolix

This study followed pregnant women who had taken elagolix (brand names Orilissa or Oriahnn) for endometriosis or uterine fibroids, along with a similar group who did not take the drug. The goal was to see if the drug increased the risk of birth defects or pregnancy complications. About 584 women were planned to join, but the study was stopped early. Participants did not receive the drug as part of the study; they just answered questionnaires during and after pregnancy.